

Active substances set

Search phrase: trastuzumab emtansine

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Malignant breast cancer

Trastuzumab emtansine	Trastuzumab Emtansine, as a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy. Trastuzumab Emtansine, as a single agent, is indicated for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: - Received prior therapy for locally advanced or metastatic disease, or - Developed disease recurrence during or within six months of completing adjuvant therapy.	FULL REIMBURSEMENT ESMO